Progesterone supplementation in the luteal phase is known to improve fertility outcomes and has become the standard for artificial reproductive technology (ART). It is based on the theory that the need for progesterone supplementation compensates for the iatrogenic luteal phase defect that is induced by the gonadotropin-releasing hormone agonist and antagonist that are used in standard in vitro fertilization (IVF) protocols.
| INTRODUC TI ON
Progesterone supplementation in the luteal phase is known to improve fertility outcomes and has become the standard for artificial reproductive technology (ART). It is based on the theory that the need for progesterone supplementation compensates for the iatrogenic luteal phase defect that is induced by the gonadotropin-releasing hormone agonist and antagonist that are used in standard in vitro fertilization (IVF) protocols. 1 A meta-analysis that evaluated 18 randomized trials showed that luteal support by the i.m. administration of progesterone or human chorionic gonadotropin (hCG) improved the pregnancy rates over those with the placebo. 2 There are three main progesterone supplementation routes:
oral, i.m., and transvaginal. The oral route is the most convenient groups. The analyses were limited to FET cycles using hormone replacement cycles with estradiol and progesterone supplementation and also were limited to blastocysts that were graded 3BB or higher. This study was approved by the authors' Institutional Ethical
Committee in accordance with ethical principles that have their origin in the Declaration of Helsinki. All the patients were well informed and written informed consent was obtained prior to the treatment period. The type of treatment that is investigated in the present study already has been discussed in other studies that have shown positive outcomes. Computing, Vienna, Austria). 16 P-values of <.01 were considered to be significant in the present study. Table 1 summarizes the baseline characteristics of the cases that were examined in the present study. Among the 2010 cases, 1188 were treated with 1200 mg, while 822 were treated with 900 mg of progesterone. Differences in the numbers were based on the study duration (27 and 20 months) and no significant difference was noted in the age or the number of ART experiences between the two groups. Among the indications for ART, the tubular factor was the most common in both groups and similar ratios were observed among all factors. Table 2 shows the clinical outcomes, including clinical pregnancy, chemical spontaneous abortion, live birth, serum progesterone level on luteal day 5, and the number of cases that were administered additional progesterone (serum progesterone levels on luteal day 5 were <9 ng/mL). The total clinical pregnancy and live birth rates were higher in the 1200 mg group (63.2% vs 57.5%, P < .01 and 40.4% vs 34.8%, P < .01, respectively). Conversely, the serum progesterone level on luteal day 5 was lower in the 1200 mg group (12.6 ± 5.4 vs 13.4 ± 4.1, P < .01). As a result, the rate of additional progesterone administration was higher in the 1200 mg group (23.5% vs 3.5%, P < .01). No significant difference was observed in the chemical spontaneous abortion rate between the two groups. A subgroup analysis revealed that the clinical pregnancy rates were not significantly different among the cohort of additional progesterone use or not (66.2% vs 63.5%, P = .41 in the 1200 mg group and 57.5% vs 58.6%, P = .91 in the 900 mg group).
| RE SULTS
When the clinical outcomes were compared between the cohorts of patients who were aged 37 years or younger and 37 years or older, the younger patients showed more favorable outcomes in both groups (a higher clinical pregnancy rate, higher live birth rate, and lower chemical spontaneous abortion rate). Conversely, no significant difference was observed in the serum progesterone level or the rate of additional progesterone administration between the younger and older patients. Univariate and multivariate regression analyses subsequently were conducted in order to identify the factors related to clinical pregnancy. As shown in Table 3 , the univariate analysis identified age and the progesterone dose as significant predictors of clinical pregnancy and both appeared to be independently associated with clinical pregnancy in the multivariate analysis.
TA B L E 1 Baseline characteristics of the full set of patients
The profile of 758 infants were analyzed: 587 (318 male and 269 female) and 171 (85 male and 86 female) were born to mothers of the 1200 mg and 900 mg groups, respectively. As shown in Figure 1A , no significant difference was observed in the distribution of the gestational age at birth between the two groups. The birthweight of the infants naturally increased in proportion to their gestational age at birth and no significant difference was noted between the two groups, regardless of their sex ( Figure 1B,C) .
| D ISCUSS I ON
Progesterone supplementation in the luteal phase has become the standard in ART and many types of medications are available for use. Historically, the i.m. route was the most widely used for luteal phase support because of earlier evidence of higher clinical pregnancy and delivery rates than those with the vaginal route. 17 However, with the accumulation of evidence that the vaginal route is at least equally as effective as the i.m. route, transvaginal progesterone preparations became more popular and the most widely used route in most countries. 6, 18 The vaginal route has some advantages over the i.m. route, including less pain, fewer adverse effects, and as a result, better compliance. In addition, vaginal progesterone supplementation is considered to result in high progesterone levels in the uterine endometrium, which might result in favorable effects on pregnancy outcomes. 19 Conversely, the serum progesterone concentrations were reported to be lower with the vaginal route than with the i.m. route. 20 However, currently it remains unclear whether these different pharmacokinetic characteristics affect the results of ART and thus there is no established dosing method for the transvaginal route that is optimal for luteal phase support in ART. 21 In contrast, some drugs of other dosage forms have the optimal dose for luteal phase support in ART. Patients need to be presented with a range of preparations for use, based on their effectiveness, convenience, and cost considerations. Therefore, a comparative analysis based on the different dose settings for transvaginal progesterone should have clinical value, so as to provide evidence for the optimal dosage for luteal support in ART.
In the present study, the serum progesterone concentrations were higher in the 900 mg group. This result prompted the authors to speculate that higher serum progesterone concentrations might negatively affect pregnancy outcomes. However, many patients with high serum progesterone levels became pregnant and the logistic regression analysis revealed that the serum progesterone concentrations
were not associated with clinical pregnancy. Therefore, differences in the serum progesterone concentrations were not considered to be a significant factor when the two groups were compared.
In the present study, additional progesterone supplementation was administered when the serum progesterone levels on luteal day These results indicate that the factor that resulted in better outcomes in the 1200 mg group was simply higher endometrium progesterone concentrations. To date, several studies have reported transvaginal progesterone doses in the range of 200-1200 mg. [22] [23] [24] The most popular dose that was used until recently was 600 mg/d. 18, 20 In the present study, a double dose was used in the 1200 mg group. Although it is not appropriate to directly compare the results because of the inclusion criterion of blastocysts that were graded 3BB or higher, the present study revealed higher pregnancy outcomes without any major adverse events, indicating the high efficacy of high-dose transvaginal progesterone supplementation. It currently remains unclear whether a dose that is >1200 mg could result in better outcomes. Although no study has used >1200 mg of progesterone, it might be possible in theory.
However, using more than four capsules three times daily might be inconvenient for patients and thus 1200 mg daily appears to be the upper limit for a practical dose.
In its present form, ART cannot compensate for all births that are lost by the natural decline in fertility with age. 25 Similarly, in this F I G U R E 1 A, Distribution of the gestational ages at birth among the 1200 mg group (■) and the 900 mg group (□). B, Comparison of the birthweight of the male babies by gestational age from 35-42 weeks between the 1200 mg group and the 900 mg group.
• and ◊ represent the mean values and standard deviations of the 1200 mg group and 900 mg group, respectively, with the P-values calculated by an unpaired t test in each period. C, Comparison of the birthweight of the female babies by gestational age from 35-42 weeks between the 1200 mg group and the 900 mg group.
• and ◊ represent the mean values and standard deviations of the 1200 mg group and 900 mg group, respectively, with the P-values calculated by an unpaired t test in each period
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